Correlation Between BRIM Biotechnology and Taiwan Chinsan

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both BRIM Biotechnology and Taiwan Chinsan at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BRIM Biotechnology and Taiwan Chinsan into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between BRIM Biotechnology and Taiwan Chinsan Electronic, you can compare the effects of market volatilities on BRIM Biotechnology and Taiwan Chinsan and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BRIM Biotechnology with a short position of Taiwan Chinsan. Check out your portfolio center. Please also check ongoing floating volatility patterns of BRIM Biotechnology and Taiwan Chinsan.

Diversification Opportunities for BRIM Biotechnology and Taiwan Chinsan

-0.56
  Correlation Coefficient

Excellent diversification

The 3 months correlation between BRIM and Taiwan is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding BRIM Biotechnology and Taiwan Chinsan Electronic in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Taiwan Chinsan Electronic and BRIM Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BRIM Biotechnology are associated (or correlated) with Taiwan Chinsan. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Taiwan Chinsan Electronic has no effect on the direction of BRIM Biotechnology i.e., BRIM Biotechnology and Taiwan Chinsan go up and down completely randomly.

Pair Corralation between BRIM Biotechnology and Taiwan Chinsan

Assuming the 90 days trading horizon BRIM Biotechnology is expected to under-perform the Taiwan Chinsan. But the stock apears to be less risky and, when comparing its historical volatility, BRIM Biotechnology is 1.54 times less risky than Taiwan Chinsan. The stock trades about -0.22 of its potential returns per unit of risk. The Taiwan Chinsan Electronic is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  3,500  in Taiwan Chinsan Electronic on September 27, 2024 and sell it today you would earn a total of  850.00  from holding Taiwan Chinsan Electronic or generate 24.29% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

BRIM Biotechnology  vs.  Taiwan Chinsan Electronic

 Performance 
       Timeline  
BRIM Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days BRIM Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Taiwan Chinsan Electronic 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Taiwan Chinsan Electronic are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Taiwan Chinsan showed solid returns over the last few months and may actually be approaching a breakup point.

BRIM Biotechnology and Taiwan Chinsan Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with BRIM Biotechnology and Taiwan Chinsan

The main advantage of trading using opposite BRIM Biotechnology and Taiwan Chinsan positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BRIM Biotechnology position performs unexpectedly, Taiwan Chinsan can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taiwan Chinsan will offset losses from the drop in Taiwan Chinsan's long position.
The idea behind BRIM Biotechnology and Taiwan Chinsan Electronic pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Global Correlations
Find global opportunities by holding instruments from different markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings